Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test
Open Access
- 15 January 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Antibody Therapeutics
- Vol. 5 (1) , 55-62
Abstract
Although mRNA vaccines against SARS-CoV-2 were highly efficacious against severe illness and hospitalization, they seem to be less effective in preventing infection months after vaccination, especially with the Delta variant. Breakthrough infections might be due to higher infectivity of the variants, relaxed protective measures by the general public in “COVID-19 fatigue”, and/or waning immunity post-vaccination. Determining the neutralizing antibody levels in a longitudinal manner may address this issue, but technical complexity of classic assays precludes easy detection and quick answers. We developed a lateral flow immunoassay NeutraXpress™ (commercial name of the test kit by Antagen Diagnostics, Inc.) and tested fingertip blood samples of subjects receiving either Moderna or Pfizer vaccines at various time points. With this device, we confirmed the reported clinical findings that mRNA vaccine-induced neutralizing antibodies quickly wane after 3–6 months. Thus, using rapid tests to monitor neutralizing antibody status could help identify individuals at risk, prevent breakthrough infections, and guide social behavior to curtail the spread of COVID-19.Keywords
Funding Information
- Massachusetts Life Science Center’s Accelerating Coronavirus Testing Solutions
This publication has 29 references indexed in Scilit:
- Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodiesNature Medicine, 2021
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19Nature Communications, 2020
- A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluationNature Communications, 2020
- A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2Science, 2020
- Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spikeNature, 2020
- Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesJournal of Experimental Medicine, 2020
- Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus (VSV) pseudovirus and ACE2-overexpressing BHK21 cellsEmerging Microbes & Infections, 2020
- Mechanism and Significance of Cell Type-Dependent Neutralization of FlavivirusesJournal of Virology, 2014
- Dengue Plaque Reduction Neutralization Test (PRNT) in Primary and Secondary Dengue Virus Infections: How Alterations in Assay Conditions Impact PerformanceThe American Journal of Tropical Medicine and Hygiene, 2009